A link between thromboxane production in fibrotic liver and portal hypertension: a potential for therapeutic targeting and preventative treatment of portal hypertension fibrosis and cirrhosis

Csey, Carol
August 2003
American Journal of Gastroenterology;Aug2003, Vol. 98 Issue 8, p1681
Academic Journal
No abstract available.


Related Articles

  • Idiopathic Portal Hypertension. Boyer, J. L.; Gupta, K. P. Sen; Biswas, S. K.; Pal, N. C.; Mallick, K. C. Basu; Iber, F. L.; Basu, A. K. // Annals of Internal Medicine;Jan67, Vol. 66 Issue 1, p41 

    Presents a study which compared the clinical and pathological features between patients with noncirrhotic portal fibrosis and patients with cirrhosis and extrahepatic obstruction. Information on portal hypertension; Clinical presentation of portal hypertension in India; Symptoms of portal...

  • Understanding portal hypertension.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1861 

    Discusses information about portal hypertension. Meaning of portal hypertension; How it is caused by a condition called cirrhosis; Causes of cirrhosis; Treatments for cirrhosis and portal hypertension.

  • Medical treatment of portal hypertension and oesophageal varices. Hayes, Peter C.; Shepherd, Alan N.; Bouchier, Ian A.D. // British Medical Journal (Clinical Research Edition);9/10/1983, Vol. 287 Issue 6394, p733 

    Focuses on the medical treatment of portal hypertension and oesophageal varices. Effects of portal venous system pressure increase on portal hypertension; Correlation between hepatic cirrhosis and portal vascular resistance; Use of propranolol in portal pressure reduction.

  • Therapeutic Potential of MicroRNA: A New Target to Treat Intrahepatic Portal Hypertension? Can-Jie Guo; Qin Pan; Hua Xiong; Yu-Qi Qiao; Zhao-Lian Bian; Wei Zhong; Li Sheng; Hai Li; Lei Shen; Jing Hua; Xiong Ma // BioMed Research International;2014, Vol. 2014, p1 

    Intrahepatic portal hypertension accounts for most of the morbidity and mortality encountered in patients with liver cirrhosis, due to increased portal inflow and intrahepatic vascular resistance. Most treatments have focused only on portal inflow or vascular resistance. However, miRNA...

  • Cirrhosis: new research provides a basis for rational and targeted treatments. Iredale, John P. // BMJ: British Medical Journal (International Edition);7/19/2003, Vol. 327 Issue 7407, p143 

    The article discusses cirrhosis and the new research that provides a basis for rational and targeted treatments. Liver transplantation and antiviral treatments for hepatitis have improved the outlook for many patients with liver disease. For patients with cirrhosis, new developments herald...

  • Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis. Gao, Jin-Hang; Wen, Shi-Lei; Yang, Wen-Juan; Lu, Yao-Yao; Tong, Huan; Huang, Zhi-Yin; Liu, Zhang-Xu; Tang, Cheng-Wei // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: Increased intra-hepatic resistance to portal blood flow is the primary factor leading to portal hypertension in cirrhosis. Up-regulated expression of cyclooxygenase-2 (COX-2) in the cirrhotic liver might be a potential target to ameliorate portal hypertension. Objective: To verify...

  • Management of portal hypertension and esophageal varices ... Trevillyan, Jeanine; Carroll, Peter J. // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1851 

    Discusses information on how to manage portal hypertension, a frequent consequence of liver disease, especially alcoholic cirrhosis. Clinical findings associated with cirrhotic liver disease; Three distinct clinical phases in the management of portal hypertension; Child's criteria for hepatic...

  • Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Steib, Christian J.; Hartmann, Anna C.; Hesler, Christoph v; Benesic, Andreas; Hennenberg, Martin; Bilzer, Manfred; Gerbes, Alexander L. // Laboratory Investigation (00236837);Jul2010, Vol. 90 Issue 7, p1024 

    Recent studies have shown that the risk of variceal bleeding in patients with liver cirrhosis increases with infections such as spontaneous bacterial peritonitis (SBP). In this study, we hypothesized that pretreatment with intraperitoneal LPS may escalate portal hypertension. In fibrotic livers...

  • Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Mejias, Marc; Coch, Laura; Berzigotti, Annalisa; Garcia-Pras, Ester; Gallego, Javier; Bosch, Jaime; Fernandez, Mercedes // Gut;Apr2015, Vol. 64 Issue 4, p657 

    Objective Antiangiogenic strategies have been proposed as a promising new approach for the therapy of portal hypertension and chronic liver disease. Pigment epithelium-derived factor (PEDF) is a powerful endogenous angiogenesis inhibitor whose role in portal hypertension remains unknown....

  • CIRRHOTIC PORTAL HYPERTENSION: NEW INSIGHTS IN AN OLD SYNDROME. Pollo-Flores, Priscila; Soldan, Mônica; da Motta Rezende, Guilherme Ferreira // Saúde e Pesquisa;mai-ago2015, Vol. 8 Issue 2, p389 

    Liver Cirrhosis is currently understood as a pathological systemic process, inflammatory, vascular and, overall, dynamic and bidirectional. The intrahepatic circulation is the site of pronounced and determinant alterations characterized by the increase of mechanical resistance to the portal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics